240 related articles for article (PubMed ID: 9661740)
21. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
22. States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Hamed SA; Fida NM; Hamed EA
Eur J Paediatr Neurol; 2009 May; 13(3):261-8. PubMed ID: 18586538
[TBL] [Abstract][Full Text] [Related]
23. Clinical validation and implications of dried blood spot sampling of carbamazepine, valproic acid and phenytoin in patients with epilepsy.
Kong ST; Lim SH; Lee WB; Kumar PK; Wang HY; Ng YL; Wong PS; Ho PC
PLoS One; 2014; 9(9):e108190. PubMed ID: 25255292
[TBL] [Abstract][Full Text] [Related]
24. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.
Kondo T; Otani K; Hirano T; Kaneko S; Fukushima Y
Br J Clin Pharmacol; 1990 Jan; 29(1):116-9. PubMed ID: 2105099
[TBL] [Abstract][Full Text] [Related]
25. Increased valproate serum concentrations upon carbamazepine cessation.
Jann MW; Fidone GS; Israel MK; Bonadero P
Epilepsia; 1988; 29(5):578-81. PubMed ID: 3137021
[TBL] [Abstract][Full Text] [Related]
26. Interactions of valproic acid with carbamazepine and its metabolites' concentrations, concentrations ratios, and level/dose ratios in epileptic children.
Liu H; Delgado MR; Browne RH
Clin Neuropharmacol; 1995 Feb; 18(1):1-12. PubMed ID: 8665529
[TBL] [Abstract][Full Text] [Related]
27. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
[TBL] [Abstract][Full Text] [Related]
28. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
[TBL] [Abstract][Full Text] [Related]
29. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy.
Wang P; Yin T; Ma HY; Liu DQ; Sheng YH; Wang C; Zhou BT
Epilepsy Res; 2015 Nov; 117():52-7. PubMed ID: 26421491
[TBL] [Abstract][Full Text] [Related]
30. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients.
McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
Epilepsy Res; 1992 May; 11(3):193-8. PubMed ID: 1396534
[TBL] [Abstract][Full Text] [Related]
31. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine.
Battino D; Croci D; Granata T; Bernardi G; Monza G
Ther Drug Monit; 1992 Oct; 14(5):376-9. PubMed ID: 1448844
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic interactions among phenobarbital, carbamazepine, and valproic acid in pediatric Japanese patients: clinical considerations on steady-state serum concentration-dose ratios.
Yukawa E; Hokazono T; Satou M; Ohdo S; Higuchi S; Aoyama T
Am J Ther; 2000 Sep; 7(5):303-8. PubMed ID: 11317175
[TBL] [Abstract][Full Text] [Related]
33. Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy.
Galimberti CA; Mazzucchelli I; Arbasino C; Canevini MP; Fattore C; Perucca E
Epilepsia; 2006 Sep; 47(9):1569-72. PubMed ID: 16981874
[TBL] [Abstract][Full Text] [Related]
34. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study.
Rättyä J; Pakarinen AJ; Knip M; Repo-Outakoski M; Myllylä VV; Isojärvi JI
Neurology; 2001 Aug; 57(3):440-4. PubMed ID: 11502910
[TBL] [Abstract][Full Text] [Related]
35. Valproate population pharmacokinetics in children.
Serrano BB; García Sánchez MJ; Otero MJ; Buelga DS; Serrano J; Domínguez-Gil A
J Clin Pharm Ther; 1999 Feb; 24(1):73-80. PubMed ID: 10319910
[TBL] [Abstract][Full Text] [Related]
36. Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: the clinical implication.
Kong ST; Lim SH; Chan E; Ho PC
J Clin Pharmacol; 2014 Feb; 54(2):225-33. PubMed ID: 23996245
[TBL] [Abstract][Full Text] [Related]
37. Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment.
Zuberi NA; Baig M; Bano S; Batool Z; Haider S; Perveen T
Neurosciences (Riyadh); 2017 Apr; 22(2):114-118. PubMed ID: 28416782
[TBL] [Abstract][Full Text] [Related]
38. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate.
Verrotti A; Laus M; Scardapane A; Franzoni E; Chiarelli F
Eur J Endocrinol; 2009 Jan; 160(1):81-6. PubMed ID: 18984773
[TBL] [Abstract][Full Text] [Related]
39. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
Vaz J; Kulkarni C; David J; Joseph T
Indian J Exp Biol; 1998 Jan; 36(1):112-4. PubMed ID: 9536660
[TBL] [Abstract][Full Text] [Related]
40. Metabolic syndrome and anticonvulsants: A comparative study of valproic acid and carbamazepine.
Rakitin A; Kõks S; Haldre S
Seizure; 2016 May; 38():11-6. PubMed ID: 27061880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
